TSHR and Graves disease: Treatment of the early TSHR-immunized mice with linsitinib improved the disease and only 11.1% of the mice showed a mild-moderate autoimmune hyperthyroidism, whereas 88.9% showed a normal thyroid function (Figure 9B).